Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 25, 2025 09:00 ET | Source: Femasys Inc.

Femasys Accelerates European Growth for FemBloc® with Kebomed Partnership

ATLANTA, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective...
September 02, 2025 09:00 ET | Source: Femasys Inc.

Femasys Closes $8 Million in Financing to Accelerate Commercialization of Fertility and Birth Control Portfolios

--Existing investors, including Femasys’ largest shareholders, reaffirm confidence in Femasys’ strategy for growth and impact in women’s health-- ATLANTA, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Femasys...
August 20, 2025 09:00 ET | Source: Femasys Inc.

Femasys Secures UK Regulatory Approval of FemBloc Permanent Birth Control

--Advances European commercialization strategy following CE mark approval-- ATLANTA, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making...
August 06, 2025 09:00 ET | Source: Femasys Inc.

Femasys Secures First European Order for FemBloc, Marking Strategic Milestone in Global Expansion

--Initiation of access to FemBloc, a revolutionary non-surgical permanent contraceptive, as global availability accelerates-- ATLANTA, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY),...
July 22, 2025 08:50 ET | Source: Bonafide® Health, LLC

5th Annual State of Menopause Study, Long-Running Survey of Menopausal Women in US, Reveals Perimenopause May be Most Misunderstood Health Transition

New York, NY, July 22, 2025 (GLOBE NEWSWIRE) -- Bonafide Health, LLC, a women’s healthcare company that provides hormone-free, clinically researched solutions to effectively relieve perimenopause...
July 01, 2025 09:00 ET | Source: Femasys Inc.

Femasys Achieves Australian and New Zealand Regulatory Approvals for FemaSeed® for First-Line Infertility Treatment and FemVue Diagnostic

-- Milestone expands global reach and reinforces commitment to accessible, first-line infertility solutions -- ATLANTA, July 01, 2025 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading...
June 25, 2025 09:00 ET | Source: Femasys Inc.

Femasys Announces Historic Milestone with European Approval of FemBloc®, the First Non-Surgical Permanent Birth Control

ATLANTA, June 25, 2025 (GLOBE NEWSWIRE) -- Femasys Inc., (Nasdaq: FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of...
May 08, 2025 17:01 ET | Source: Femasys Inc.

Femasys Announces Financial Results for Quarter Ended March 31, 2025, and Provides Corporate Update

-- Company delivers on mission to transform women’s health with innovative solutions, including FemaSeed® for first-line infertility treatment and FemBloc® non-surgical permanent birth control (full...
March 18, 2025 09:00 ET | Source: Femasys Inc.

Femasys Secures Distribution Partnerships for Commercialization of FemBloc® in Spain

-- Company taps first EU distributors, Comercial Medico Quirurigca, SA and Durgalab, as the first globally to be granted rights to commercialize FemBloc® -- ATLANTA, March 18, 2025 (GLOBE NEWSWIRE)...
March 13, 2025 08:30 ET | Source: Femasys Inc.

Femasys Announces FemBloc Delivery System Approval in Europe; A Significant Step Towards FemBloc Permanent Birth Control Availability as the First-Ever Non-Surgical Approach

ATLANTA, March 13, 2025 (GLOBE NEWSWIRE) -- Femasys Inc., (Nasdaq: FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of...